Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Topiramate and phentermine: a long story....

[No authors listed]

Prescrire Int. 2013 Mar;22(136):62. No abstract available.

PMID:
23593687
2.

Topiramate + phentermine. An excessively dangerous appetite-suppressant combination.

[No authors listed]

Prescrire Int. 2013 Mar;22(136):61-4.

PMID:
23593686
3.

Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.

Bays H.

Expert Rev Cardiovasc Ther. 2010 Dec;8(12):1777-801. doi: 10.1586/erc.10.125. Epub 2010 Aug 16. Review.

PMID:
20707765
4.

Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity.

Bays HE, Gadde KM.

Drugs Today (Barc). 2011 Dec;47(12):903-14. doi: 10.1358/dot.2011.47.12.1718738. Review. Erratum in: Drugs Today (Barc). 2012 Jan;48(1):95.

PMID:
22348915
5.

Phentermine and topiramate extended release (Qsymia™): first global approval.

Cameron F, Whiteside G, McKeage K.

Drugs. 2012 Oct 22;72(15):2033-42. doi: 10.2165/11640860-000000000-00000.

PMID:
23039320
6.

What cost weight loss?

Hiatt WR, Thomas A, Goldfine AB.

Circulation. 2012 Mar 6;125(9):1171-7. doi: 10.1161/CIRCULATIONAHA.111.023499. No abstract available.

7.

Phentermine/topiramate for the treatment of obesity.

Smith SM, Meyer M, Trinkley KE.

Ann Pharmacother. 2013 Mar;47(3):340-9. Review.

PMID:
23482732
9.

Combination phentermine and topiramate for weight maintenance: the first Australian experience.

Neoh SL, Sumithran P, Haywood CJ, Houlihan CA, Lee FT, Proietto J.

Med J Aust. 2014 Aug 18;201(4):224-6.

PMID:
25164851
10.

Two anti-obesity hopefuls and their safety.

Bello NT, Campbell SC.

Expert Opin Drug Saf. 2012 Sep;11(5):681-3. doi: 10.1517/14740338.2012.706277. Epub 2012 Jul 13. No abstract available.

PMID:
22788876
11.

Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss.

Kelly EM, Tungol AA, Wesolowicz LA.

J Manag Care Pharm. 2013 Oct;19(8):642-54. Review.

12.

Phentermine plus topiramate in the treatment of obesity.

Malgarini RB, Pimpinella G.

Lancet. 2011 Jul 9;378(9786):125-6; author reply 126-7. doi: 10.1016/S0140-6736(11)61080-5. No abstract available.

PMID:
21742167
13.

[Qnexa: a new anti-obesity threat].

Nau JY.

Rev Med Suisse. 2012 May 16;8(341):1076-7. French. No abstract available.

PMID:
22730646
14.
15.

New obesity agents: lorcaserin and phentermine/topiramate.

Fleming JW, McClendon KS, Riche DM.

Ann Pharmacother. 2013 Jul-Aug;47(7-8):1007-16. doi: 10.1345/aph.1R779. Epub 2013 Jun 25. Review.

PMID:
23800750
16.
17.

Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity.

Jordan J, Astrup A, Engeli S, Narkiewicz K, Day WW, Finer N.

J Hypertens. 2014 Jun;32(6):1178-88. doi: 10.1097/HJH.0000000000000145. Review.

18.

Phentermine plus topiramate in the treatment of obesity.

Cohen PA.

Lancet. 2011 Jul 9;378(9786):126; author reply 126-7. doi: 10.1016/S0140-6736(11)61081-7. No abstract available.

PMID:
21742168
19.

Lorcaserin and phentermine/topiramate: two leaps forward in weight loss pharmacotherapy.

Hill LG.

Ann Pharmacother. 2013 Dec;47(12):1740. doi: 10.1177/1060028013513557. No abstract available.

PMID:
24396110
20.

Response to "lorcaserin and phentermine/topiramate: two leaps forward in weight loss pharmacotherapy".

Fleming JW, McClendon KS, Riche DM.

Ann Pharmacother. 2013 Dec;47(12):1741. doi: 10.1177/1060028013513884. Epub 2013 Dec 5. No abstract available.

PMID:
24311729

Supplemental Content

Support Center